Want to see PPCB full AI Analyst Report?
Propanc Biopharma (PPCB) Stock Statistics & Valuation Metrics
Total Valuation
Propanc Biopharma has a market cap or net worth of $1.90M. The enterprise value is $4.64M.
- Market Cap
- $1.90M
- Enterprise Value
- $4.64M
Share Statistics
Propanc Biopharma has 1,033,112 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,033,112
- Owned by Insiders
- ―
- Owned by Institutions
- 3.67%
Financial Efficiency
Propanc Biopharma’s return on equity (ROE) is -2.01 and return on invested capital (ROIC) is -192.44%.
- Return on Equity (ROE)
- -2.01
- Return on Assets (ROA)
- -1.48
- Return on Invested Capital (ROIC)
- -192.44%
- Return on Capital Employed (ROCE)
- -1.93
- Revenue Per Employee
- 0
- Profits Per Employee
- -9.43M
- Employee Count
- 2
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Propanc Biopharma is -0.01. Propanc Biopharma’s PEG ratio is -0.00.
- PE Ratio
- -0.01
- PS Ratio
- 0.00
- PB Ratio
- 0.02
- Price to FCF
- -0.33
- Price to Operating Cash Flow
- -0.04
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Propanc Biopharma had revenue of 0 and earned -18.86M in profits. Earnings per share was -17.62.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -18.19M
- Pretax Income
- -18.86M
- Net Income
- -18.86M
- EBITDA
- -18.41M
- Earnings Per Share (EPS)
- -17.62
Cash Flow
In the last 12 months, operating cash flow was -5.69M and capital expenditures -21, giving a free cash flow of -5.69M billion.
- Operating Cash Flow
- -5.69M
- Free Cash Flow
- -5.69M
- Free Cash Flow per Share
- -50.62
Dividends & Yields
Propanc Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -299.22%
- Earnings Yield
- -9122.88%
Stock Price Statistics
- Beta
- -0.64
- 52-Week Price Change
- -99.41%
- 50-Day Moving Average
- 6.71
- 200-Day Moving Average
- 21.93
- Relative Strength Index (RSI)
- 21.17
- Average Volume (3m)
- 189.13K
Important Dates
Propanc Biopharma upcoming earnings date is Nov 23, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Sep 29, 2026
- Next Earnings Date
- Nov 23, 2026
- Ex-Dividend Date
- ―
Financial Position
Propanc Biopharma as a current ratio of 2.55, with Debt / Equity ratio of 0.51%
- Current Ratio
- 2.55
- Quick Ratio
- 2.55
- Debt to Market Cap
- 0.03
- Net Debt to EBITDA
- 0.04
- Interest Coverage Ratio
- -42.24
Taxes
In the past 12 months, Propanc Biopharma has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Propanc Biopharma EV to EBITDA ratio is -0.09, with an EV/FCF ratio of -0.28.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.09
- EV to Free Cash Flow
- -0.28
- EV to Operating Cash Flow
- -0.28
Balance Sheet
Propanc Biopharma has $832.01K in cash and marketable securities with $509.12K in debt, giving a net cash position of $322.89K billion.
- Cash & Marketable Securities
- $832.01K
- Total Debt
- $509.12K
- Net Cash
- $322.89K
- Net Cash Per Share
- $0.31
- Tangible Book Value Per Share
- $83.67
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Propanc Biopharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 98.74%
Scores
- Smart Score
- ―
- AI Score
- 41